Empagliflozin
Brand names: Jardiance
Part of: SGLT2 diabetes & heart drugs
At a glance
- Medicare prescriptions, 2024
- 10,508,963
- Medicare drug cost
- $10.53B
- Average cost per prescription
- $1,002
- Clinicians who prescribed it
- 195,554
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 27.0%
- Internal Medicine 23.4%
- Nurse Practitioners 18.1%
- Endocrinology & Diabetes 8.0%
- Cardiology 6.7%
- Physician Assistants 6.1%
- Nephrology (Kidney) 3.0%
- Interventional Cardiology 1.9%
- General Practice 1.1%
- Geriatric Medicine 1.1%
- Heart Failure & Transplant Cardiology 1.0%
- Pharmacists 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 527% from 2019 to 2024.
Biggest change by state since 2019
- Minnesota +950%
- Colorado +894%
- Oregon +892%
- Michigan +852%
- Washington +821%
- New Jersey (smallest change) +328%
- Kentucky (smallest change) +367%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Aphena Pharma Solutions - Tennessee, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg | yellow round tablet, 9 mm | S 10 |
Boehringer Ingelheim Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 5 mg / 1000 mg metformin hydrochloride | brown oval tablet, 21 mm | S5 1000 |
| 5 mg / 500 mg metformin hydrochloride | orange oval tablet, 16 mm | S5 500 |
| 12.5 mg / 1000 mg metformin hydrochloride | purple oval tablet, 21 mm | S12 1000 |
| 12.5 mg / 500 mg metformin hydrochloride | purple oval tablet, 16 mm | S12 500 |
Redpharm Drug
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow oval tablet, 11 mm | S 25 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $8.8M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Boehringer Ingelheim Pharmaceuticals, Inc. $5.8M
- Lilly USA, LLC $2.8M
- Boehringer Ingelheim International GmbH $112,660
- Boehringer Ingelheim Rcv GmbH & Co Kg $66,165
- Eli Lilly and Company $26,970
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Mar 2023 · Boehringer Ingelheim Pharmaceuticals, Inc. · Class II
Labeling: Label Mix-up - Jan 2022 · Cardinal Healthcare · Class II
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.